Cyclacel Pharmaceuticals Inc. announced a change in its independent registered public accounting firm. Effective August 22, 2025, the company's Audit Committee approved the dismissal of Bush & Associates CPA LLP, following the firm's advisory that Cyclacel does not currently have sufficient funds to complete its development and commercialization efforts, raising substantial doubt about the company's ability to continue operations. No disagreements were noted between Cyclacel and Bush regarding accounting principles or practices. The company has engaged SFAI Malaysia PLT as its new auditor, effective August 23, 2025. Cyclacel has authorized Bush to respond fully to SFAI's inquiries regarding the situation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cyclacel Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-025752), on August 28, 2025, and is solely responsible for the information contained therein.